Recuento de células CD34+ por citometría de flujo
Autores
Esteban Jara-Segura, Evan Jensen-Gamboa
Resumen
Los trasplantes de células madre hematopoyéticas (CMH) han sido fundamentales para la restitución de la hematopoyesis en el hombre: esta práctica clínica se ha llevado a cabo desde los años 50, y se ha determinado que el éxito de este procedimiento no solo se asocia con la compatibilidad que debe existir entre el donador y el receptor, también en el número adecuado de células CD34+. Este se ha convertido en el parámetro clínico de mayor importancia.
La citometría de flujo (CF) es el método de elección para la identificación de células CD34+. El protocolo más recomendado es la utilización de plataforma única y evaluación de la viabilidad celular. En este artículo se describen los diferentes procesos; sus ventajas y desventajas, y la forma correcta del análisis con base en los lineamientos de la Sociedad Internacional de Hemoterapia e Ingeniería de Injertos (ISHAGE).
Palabras clave
células madre hematopoyéticas, citometría de flujo, plataforma doble, plataforma única, trasplante de células madre.Abstract
Hematopoietic stem cell transplantation (CMH) has been fundamental to the restoration of hematopoiesis in man: this clinical practice has been carried out since the 1950s, and it has been determined that the success of this procedure is not only associated with the compatibility that must exist between the donor and recipient, but also with the appropriate number of CD34 + cells. This has become the most important clinical parameter.
Flow cytometry (CF) is the method of choice for the identification of CD34 + cells. The most recommended protocol is the use of a single platform and evaluation of cell viability. This article describes the different processes; their advantages and disadvantages, as well as the correct form of analysis based on the guidelines of the International Society of Hemotherapy and Graft Engineering (ISHAGE).
Key words
stem cell hematopoietic, Cytometry flow, dual platform, single platform, stem cell transplant.Texto completo
Referencias
1. Salmen S, Silva N, Bahsas R, Terán G, Barboza L, Padrón K; et al. Células progenitoras pluripotenciales: Características y compartimentos especializados de residencia. Avances en Biomedicina 2013 Vol.2, 1, 26-38.
2. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993; 81: 2844-53.
3. Sutherland R, Keating A. The CD34 Antigen: Structure, Biology, and Potential Clinical Applications. Journal of Hematotherapy 1992; 1:115-129
4. Sutherland DR, Anderson L, Keeney M, Rayash N, Chin Yee I. The ISHAGE Guidelines for CD34+ Cell Determination by Flow Citometry. Journal of Hemotherapy 1996; 5:213-226.
5. Pranke P, Hendrix J, Alespeiti G, Nardi N, Rubinstein P, Visse J. Comparative quantification of umbilical cord blood CD34+ and CD34+ bright cells using the ProCount TM-BD and ISHAGE protocols. Q Brazilian Journal of Medical and Biological Research 2006; 39: 901-906
6. Reya T, Morrison S, Clarke M, Weissman L. Stem cells, cancer, and stem cells. Nature 2001; 414:105-111.
7. Passweg J, Halter J, Bucher C, Gerull S, Heim D, Rovó A, Buser A, Stern M, Tichelli A. Hematopoietic stem cell transplantation: a review and recommendations for follow-up care for the general practitioner 2012; Swiss Med Wkly. 2012;142: w13696.
8. Leuner S, Arland M, Kahl C, Jentsch-Ulrich K, Franke a, Hoffkes HG. Enumeration of CD34-positive hematopoietic progenitor cells by flow cytometry: comparison of a volumetric assay and the ISHAGE gating strategy. Bone Marrow Trasnplantation 1998; 22: 609-706.
9. Ngmoa A, Saito S, Ohto H, Ikeada K, Yasuda H, Kawabata K, Kanno T, Kikuta A, Mochiziki K, Nollet K. CD34+ Cell Enumeration by Flow Cytometry: A Comparison of Systems and Methodologies. Arch Pathol Lab Med 2011; Vol 135.
10. Armitage S, Hargreaves R, Samosn D, Brennan M, Kanfer E, Navarrete C. CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplantation 1997; 20: 587-591
11. Fukuda J, Kaneko T, Egashira M, Oshimi K. Direct Measurement of CD34+ Blood Stem Cell Absolute Counts by Flow Cytometry. Stem Cells 2001; 16:294-300.
12. Deeg H, Klingemann H, Phillips G, Zant G. A Guide to Blood and Marrow Transplantation. Springer-Verlag Berlin Heidelberg. 1999.
13. Keeney M, Gratama JW, Sutherland DR. Critical role of flow cytometry in evaluating peripheral blood hematopoietic stem cells graft. Journal of Quantitative Cell Science, Cytometry A 2004; 58: 72-75. https://doi.org/10.1002/cyto.a.10103
14. Gratama JW, Menendez P, Kraan J, Orfao A. Loss of CD34 hematopoietic progenitor cells due to washing can be reduced by the use of fixative-free erythrocyte lysing reagents. Journal of Immunological Methods 2000; 239 13–23.
15. Gould D, Kessler D. FDA Regulation of Stem-Cell-Based Therapies. N Engl J Med 2006; 355:1730-1735.
16. European Pharmacopoeia. Monograph 2.7.23: Numeration of CD34/CD45 Cells in Haematopoietic Products. European Pharmacopoeia, 2007.
17. Decreto Ejecutivo N° 39986-S. La Gaceta Diario Oficial. San José, Costa Rica, 8 de noviembre del 2016.
18. Zumbado G, Rodríguez M, Rojas X, Rojas C, Herrera H. Recolección de células madre en sangre periférica mediante aféresis de grandes volúmenes. Acta Med Costarric. 2014. Vol 56 (2).
19. Levering W, Preijers F, van Wieringen W, Kraan J, van Beers, Sintnicolaas K; et al. Flow Cytometric CD34+ Stem cell Enumeration: Lesson from nine year’s external quality assessment within the Benelux countries. Cytometry Part A 2007; 58A: 72-75.
20. Whitby A, Whitby L, Fletcher M, Reilly JT, Sutherland DR, Keeney M, Barnett D. ISHAGE protocol: Are we doing it correctly? Cytometry Part B. 2012; 82B: 9–17.
21. Gajkowska A, Oldak T, Jastrzewska M, Machaj EK, Walewski J, Kraszewska E; et al. Flow cytometric enumeration of CD34+ hematopoietic stem and progenitor cells in leukapheresis product and bone marrow for clinical transplantation: a comparison of three methods. Folia Histochem Cytobiol. 2006; 44(1): 53-60.